def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Filed by the
Registrant þ
Filed by a Party other than the
Registrant o
Check the appropriate box:
o Preliminary
Proxy Statement
o Confidential,
for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
þ Definitive
Proxy Statement
o Definitive
Additional Materials
o Soliciting
Material Pursuant to
§ 240.14a-12
CAS MEDICAL SYSTEMS, INC.
(Name of Registrant as Specified In
Its Charter)
(Name of Person(s) Filing Proxy
Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|
|
þ
|
No fee required.
|
|
o
|
Fee computed on table below per Exchange Act
Rules 14a-6(i)(1)
and 0-11.
|
|
|
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
|
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
|
|
|
(3)
|
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act
Rule 0-11
(set forth the amount on which the filing fee is calculated and
state how it was determined):
|
|
|
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
|
o
|
Fee paid previously with preliminary materials.
|
|
o
|
Check box if any part of the fee is offset as provided by
Exchange Act
Rule 0-11(a)(2)
and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its
filing.
|
|
|
|
|
(1)
|
Amount Previously Paid:
|
|
|
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
April 26, 2010
Dear Fellow Stockholder:
We will hold our 2010 annual meeting of stockholders at
10:30 a.m. on Wednesday, June 9, 2010 at The
WoodWinds, 29 Schoolground Road, Branford, Connecticut.
The notice of annual meeting, proxy statement and proxy card
accompanying this letter describe in detail the matters to be
acted upon at the meeting.
It is important that your shares be represented at the meeting.
Whether or not you plan to attend, please sign, date and return
your proxy card in the enclosed envelope as soon as possible.
We look forward to seeing you at the meeting.
Sincerely yours,
Louis P. Scheps
Chairman of the Board
CAS
MEDICAL SYSTEMS, INC.
NOTICE OF ANNUAL MEETING
The annual meeting of stockholders of CAS Medical Systems, Inc.
will be held at 10:30 a.m. on Wednesday, June 9, 2010
at The WoodWinds, 29 Schoolground Road, Branford, Connecticut.
The items of business at the annual meeting are:
|
|
|
|
1.
|
Election of six directors.
|
|
|
|
|
2.
|
Appointment of independent accountants for 2010.
|
|
|
3.
|
Such other matters as may properly come before the meeting,
including any continuation of the meeting caused by any
adjournment or any postponement of the meeting.
|
April 21, 2010 is the record date for the meeting.
This Proxy Statement and accompanying proxy card are being
distributed on or about April 28, 2010.
Jeffery A. Baird
Secretary
THIS PROXY STATEMENT AND THE 2009 ANNUAL REPORT ARE AVAILABLE
AT WWW.CASMED.COM.
CAS
MEDICAL SYSTEMS, INC.
44 East Industrial Road
Branford, Connecticut 06405
PROXY
STATEMENT
The
Annual Meeting and Voting
Our board of directors is soliciting proxies to be used at the
annual meeting of stockholders to be held on Wednesday,
June 9, 2010, or at any adjournment of the meeting. This
proxy statement contains information about the items being voted
on at the annual meeting.
Who is
entitled to vote?
Record stockholders of CAS Medical Systems, Inc. (CASMED) common
stock at the close of business on April 21, 2010 (the
record date) can vote at the meeting. As of the record date,
11,531,584 shares of CASMED common stock were issued and
outstanding. Each stockholder has one vote for each share of
common stock owned as of the record date. A list of all
stockholders entitled to vote at the meeting will be available
for examination by any stockholder for any purpose germane to
the meeting at our office at 44 East Industrial Road, Branford,
Connecticut, for the
ten-day
period immediately preceding the meeting.
How do I
vote?
A form of proxy card and a return envelope for the proxy card
are enclosed. Giving your proxy means that you authorize the
persons named in the enclosed proxy card to vote your shares at
the CASMED annual meeting in the manner you direct. You may vote
by proxy or in person at the annual meeting. To vote by proxy,
if you are a registered holder, please complete, sign and return
your proxy card in the accompanying postage-paid return envelope.
If any proxy is returned without indication as to how to vote,
the CASMED common stock represented by the proxy will be voted
by the persons named on the proxy in favor of each proposal and
in accordance with their best judgment on any other matters
which may come before the meeting.
How do I
vote if my shares are held in street name?
If your broker holds your shares of CASMED common stock in
street name, you must either direct your broker on how to vote
your shares or obtain a proxy from your broker to vote in person
at the annual meeting. If your shares are held in street name,
you should check the voting form that you receive to determine
whether shares may be voted by telephone or the internet.
May I
change my vote?
You may revoke your proxy at any time before it is voted at the
meeting in several ways. You may (i) send in a revised
proxy dated later than the first, (ii) vote in person at
the meeting, or (iii) notify our Secretary in writing prior
to the meeting that you have revoked your proxy.
What
constitutes a quorum?
The holders of a majority of the outstanding shares entitled to
vote at the meeting, present in person or represented by proxy,
constitute a quorum. Abstentions, broker non-votes and votes
withheld from director nominees are included in the count to
determine a quorum. If a quorum is present, each of the six
director candidates who receive a majority of the votes of the
shares present in person or represented by proxy and entitled to
vote on the election of directors will be elected.
Proposal 2 will be approved if a quorum is present and a
majority of the votes cast by holders present in person or
represented by proxy are cast in favor of the applicable
proposal.
What is
the effect of broker non-votes and abstentions?
Under Nasdaq rules, if your broker holds your shares in its
street name, the broker may under certain
circumstances vote your shares on the agenda items even if it
does not receive instructions from you. Because broker non-votes
and abstentions are not considered votes cast on the matters
before the meeting, neither will have an effect on the voting
for these proposals.
Stockholder
proposals for the 2011 annual meeting
Stockholder proposals intended to be presented at our 2011
annual meeting pursuant to
Securities Exchange Act
Rule 14a-8
must be received by our Secretary not later than
December 26, 2010, for inclusion in our proxy statement and
form of proxy relating to that meeting. Stockholder proposals
submitted outside the process provided in
Rule 14a-8
shall be considered untimely in accordance with
Rule 14a-5(e)
if made after March 11, 2011.
Which
stockholders own at least 5% of CASMED?
Other than a director listed in the director and officer
ownership table below, the only persons or groups known to us to
be beneficial owners of more than five percent of our
outstanding common stock as of April 21, 2010 are reflected
in the chart below. The following information is based upon
Schedules 13D, 13F and 13G respectively filed with the
Securities and Exchange Commission by the persons and entities
shown as of the respective dates appearing below or other
information obtained by the company.
|
|
|
|
|
|
|
|
|
Name and Address of
|
|
Amount and Nature of
|
|
|
Beneficial Owners
|
|
Beneficial Ownership
|
|
Percent of Class
|
|
BMI Capital Corporation
|
|
|
2,292,583
|
(a)
|
|
|
19.9
|
%
|
570 Lexington Avenue
New York, NY 10022
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
J. Sanford Davis
|
|
|
921,500
|
|
|
|
8.0
|
%
|
14 Longview Terrace
Madison, CT 06443
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
Based upon information set forth in a Schedule 13F filed
with the SEC on February 10, 2010. BMI Capital Corporation
holds sole dispositive power over the indicated shares. |
2
How much
stock is owned by directors and executive officers?
The following table shows beneficial ownership of CASMED common
stock as of April 21, 2010 by our directors and our
executive officers and a former executive officer named in the
compensation tables in this proxy statement. Shares issuable
upon exercise of options or warrants are shown in a separate
column.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options and
|
|
|
|
|
Shares Deemed to be
|
|
Warrants
|
|
|
|
|
Beneficially Owned
|
|
Exercisable Within
|
|
Percent
|
Name of Beneficial Owner
|
|
(a)
|
|
60 Days (b)
|
|
of Class
|
|
Louis P. Scheps
|
|
|
184,807
|
|
|
|
714,401
|
|
|
|
7.3
|
%
|
Jerome Baron
|
|
|
118,582
|
|
|
|
7,500
|
|
|
|
1.1
|
%
|
Lawrence S. Burstein
|
|
|
96,257
|
(c)
|
|
|
115,000
|
|
|
|
1.8
|
%
|
Evan Jones
|
|
|
355,374
|
|
|
|
13,333
|
|
|
|
3.2
|
%
|
Kenneth R. Weisshaar
|
|
|
|
|
|
|
|
|
|
|
|
|
Andrew E. Kersey
|
|
|
40,658
|
|
|
|
150,000
|
|
|
|
1.6
|
%
|
Jeffery A. Baird
|
|
|
33,711
|
|
|
|
110,000
|
|
|
|
1.2
|
%
|
Nathan B. Harris (d)
|
|
|
2,500
|
|
|
|
|
|
|
|
|
*
|
All current executive officers and
directors as a group (7)
|
|
|
829,389
|
|
|
|
1,110,234
|
|
|
|
15.3
|
%
|
|
|
|
* |
|
Less than one percent of the class |
|
|
|
(a) |
|
Includes restricted stock held by the named individuals as
follows: Mr. Scheps 1,470 shares;
Mr. Baron 1,470 shares;
Mr. Burstein 1,470 shares;
Mr. Jones 1,470 shares;
Mr. Kersey 8,334 shares; and
Mr. Baird 6,500 shares. |
|
(b) |
|
The director or executive officer has the right to acquire
beneficial ownership of this number of shares within
60 days of the record date for the annual meeting
(April 21, 2010) by exercising outstanding stock
options or warrants (as applicable). |
|
(c) |
|
Includes 75,000 shares held in Mr. Bursteins IRA
rollover account and 9,375 shares owned directly and
indirectly by a family member. |
|
(d) |
|
Beneficial ownership information for Mr. Harris is as of
August 15, 2009. Mr. Harris resigned from the Company
as of that date. |
Section 16(a)
Beneficial Ownership Reporting Compliance
Directors and persons who are considered officers of
the company for purposes of Section 16(a) of the Securities
Exchange Act of 1934 and greater than ten percent stockholders
(referred to as reporting persons) are required to file reports
with the Securities and Exchange Commission showing their
holdings of and transactions in CASMED securities. It is
generally our practice to file the forms on behalf of our
reporting persons who are directors or officers. We believe that
all such forms have been timely filed for 2009.
3
Proposal 1:
Election
of Directors
Six directors, constituting the entire board of directors of
CASMED, are to be elected at the annual meeting to serve for a
term of one year or until their respective successors are duly
elected and qualify. Information about each nominee for director
(all of whom are incumbent directors), including the
nominees age, is set forth below. Unless otherwise
indicated, each nominee has held his present position for at
least five years. The shares represented by the proxies will be
voted in favor of the election as directors of the persons named
below unless authority to do so is withheld. Should you choose
not to vote for a nominee, you may list on the proxy the name of
the nominee for whom you choose not to vote and mark your proxy
under Proposal No. 1 for all other nominees. Should
any nominee become unable to accept nomination or election as a
director (which is not now anticipated), the persons named in
the enclosed proxy will vote for a substitute nominee as may be
selected by the board of directors, unless the size of the board
is reduced.
NOMINEES
FOR ELECTION TO BOARD OF DIRECTORS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year First
|
|
Principal Occupation
|
Name
|
|
Age
|
|
Became Director
|
|
During the Past Five Years
|
|
Louis P. Scheps
|
|
|
78
|
|
|
|
1990
|
|
|
Currently Chairman of the Board of CASMED. Mr. Scheps held the
positions of President and Chief Executive Officer of CASMED
from 1990 until March 2007 and held the position of Director of
Manufacturing of CASMED from 1986 until 1990. Prior thereto, Mr.
Scheps was employed by Posi-Seal International as Vice President
from 1969 to 1985. Mr. Scheps received his engineering degree
from Purdue University and his business education from the GE
Management Program. As our former Chief Executive Officer, Mr.
Scheps has extensive knowledge of the Company and considerable
experience in manufacturing operations.
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year First
|
|
Principal Occupation
|
Name
|
|
Age
|
|
Became Director
|
|
During the Past Five Years
|
|
Jerome Baron
|
|
|
83
|
|
|
|
1986
|
|
|
Mr. Baron has been in the securities industry since 1944. He
was a Vice President in the International Department at Loeb
Rhoades & Company, a Partner at Andreson & Company,
and Chairman and Chief Executive Officer of Foster Securities,
Inc., which he founded in 1974. In 1977, Foster Securities
merged with Brean Murray and Company, Inc. Mr. Baron is
Vice-Chairman of Brean Murray, Carret & Co. He is a
Director of Haulbowline Ltd., a private offshore company. He
attended Kings Point Merchant Marine Academy and Pace
University. Mr. Baron, our audit committee chairman, has
extensive knowledge of the capital markets and has been a
long-standing member of the Companys Board of Directors
where he has become very familiar with the Companys
operations.
|
Lawrence S. Burstein
|
|
|
67
|
|
|
|
1985
|
|
|
Mr. Burstein has been President and principal stockholder of
Unity Venture Capital Associates, Ltd. since March 1996. Prior
thereto he was President, a director and principal stockholder
of Trinity Capital Corporation since October 1982. Mr. Burstein
is a director of three other public companies: THQ, Inc., a
manufacturer of video game cartridges, I.D. Systems, Inc., which
designs, develops and produces a wireless monitoring and
tracking system; and Atrinsic, Inc., which is principally an
internet direct marketing company. In addition, Mr. Burstein is
a director of Millennium India Acquisition Corporation, a
publicly traded 1940 Act investment company. He was formerly a
director of American Telecom Services, Inc., a provider of
converged telecommunication services. Mr. Burstein received
an L.L.B. from Columbia Law School. Mr. Burstein has
considerable experience with respect to law and strategic
business matters across a variety of industries. He past
experience with the Company is important to the Boards
ability to evaluate our business strategies and decisions.
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year First
|
|
Principal Occupation
|
Name
|
|
Age
|
|
Became Director
|
|
During the Past Five Years
|
|
Andrew E. Kersey
|
|
|
49
|
|
|
|
2007
|
|
|
Mr. Kersey has been President and Chief Executive Officer of
CASMED since April 2007. Mr. Kersey has over 20 years
experience in the medical device industry and has been with
CASMED since 2001. Mr. Kersey served as Chief Operating Officer
of CASMED from 2004 until April 2007. Previously, Mr. Kersey was
Director of Engineering of CASMED. Prior to joining CASMED, Mr.
Kersey held various engineering management positions at
Novametrix Medical Systems, Inc. and Corometrics Medical
Systems. Mr. Kersey has extensive experience in the medical
device industry and, as our Chief Executive Officer, provides
insight to the Board with respect to the management of CASMED
and its key issues.
|
Evan Jones
|
|
|
53
|
|
|
|
2008
|
|
|
Mr. Jones was a co-founder of Digene Corporation, a publicly
traded biotechnology company focused on womens health and
molecular diagnostic testing, serving as Chairman of the Board
from 1995 through 2007. Mr. Jones was CEO of Digene from 1990 to
2006, and President from 1990 to 1999. In July 2007, Mr. Jones
formed jVen Capital, LLC, a life sciences investment company.
Mr. Jones is a member of the Board of Directors of the
Childrens National Medical Center and the Childrens
Research Institute in Washington DC. He is Chairman of the
Campaign for Public Health, an independent, not-for-profit
organization dedicated to increasing funding for the Centers for
Disease Control and Prevention, and is a member of the Board of
Directors and the Executive Committee of Research!America. Mr.
Jones received a B.A. from the University of Colorado and an
M.B.A. from The Wharton School at the University of
Pennsylvania. Mr. Jones has considerable knowledge of the
medical device market as well as experience leading a
publicly-traded company and interacting with investors and
shareholders. His experience is valuable to the Boards
ability to assess our strategy and direction and evaluate our
business decisions.
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year First
|
|
Principal Occupation
|
Name
|
|
Age
|
|
Became Director
|
|
During the Past Five Years
|
|
Kenneth R. Weisshaar
|
|
|
59
|
|
|
|
2010
|
|
|
Mr. Weisshaar currently serves as a member of the Board of
Directors of Orthofix International, N.V., a NASDAQ listed
company focusing on spine reconstruction and trauma, and
Precision Therapuetics Inc., a private oncology services
company. Mr. Weisshaar serves on the Board of Directors of
Beth Abraham Family of Health Services, a large non-profit
nursing home and managed care organization located in the
New York area. Mr. Weisshaar previously served as a member
of the Board of Directors of Digene Corporation, a publicly
traded biotechnology company focused on womens health and
molecular diagnostic testing. Mr. Weisshaar served as Chief
Operating Officer and Strategy Advisor of Sensatex, Inc. a
start-up company developing wireless vital signs monitoring
equipment from 2000 to 2002. Mr. Weisshaar previously
served in various capacities with Becton Dickinson and Company
from 1988 to 1999 including Senior Vice-President and Chief
Financial Officer from 1998 to 1999, President of Worldwide
Consumer Health Care from 1996 to 1998, Sector President from
1994-1996, Divisional President 1992-1994 and Vice President,
Corporate Planning and Development from 1988-1992. Mr. Weisshaar
was also employed by McKinsey and Company primarily as a
healthcare and manufacturing consultant from 1982 to 1988 and
held various positions with Raychem Corporation from 1974 to
1982. Mr. Weisshaar received a B.S. in Chemical Engineering
from the Massachusetts Institute of Technology and a MBA from
the Harvard Business School. Mr. Weisshaar has extensive
operating and financial management experience in the medical
device market.
|
The board
of directors recommends that stockholders vote FOR the nominees
described in Proposal 1.
Executive
Officers
Our executive officers are as follows:
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Position
|
|
Andrew E. Kersey
|
|
|
49
|
|
|
President and Chief Executive Officer
|
Jeffery A. Baird
|
|
|
56
|
|
|
Chief Financial Officer and Secretary
|
7
Information
Concerning Executive Officers Who Are Not Directors
Jeffery A. Baird joined CASMED during January 2004. From
April 2003 to December 2003, Mr. Baird was CFO of QDx,
Inc., a startup venture engaged in the development of novel
medical diagnostic products. Mr. Baird was employed by
Novametrix Medical Systems, Inc. from 1988 to 2002 and held
various positions including Controller, Treasurer and CFO. Prior
to joining Novametrix, Mr. Baird was employed by Philips
Medical Systems, Inc., a medical diagnostic imaging company.
Board
Information and Committees
The board met eight times in 2009 and acted twice by unanimous
written consent. Each incumbent director attended at least
75 percent of the total number of board meetings and
meetings held by the board committees on which he served during
2009. The board has determined that each of our non-employee
directors currently serving on the board or who served on the
board during 2009, other than Mr. Scheps who is our former
President and Chief Executive Officer, is independent based upon
the criteria provided by Nasdaq Stock Market rules. Members of
the board serve on one or more of the committees described
below, except for directors who are also employees or former
employees of the company, who do not serve on board committees.
We maintain a leadership structure for CASMED that separates the
positions of Chairman of the Board and Chief Executive Officer.
By having different individuals serve in these roles, we believe
that we provide for additional independence of and oversight by
the board of directors and enable our Chief Executive Officer to
focus his time and attention on the Companys operations
and strategic direction. Our current Chairman of the Board,
Louis P. Scheps, served as our Chief Executive Officer from 1990
until March 2007, which we believe gives him additional
experience and insight that enhances the ability of the board to
oversee CASMED and the Chief Executive Officer.
The board of directors has general risk oversight
responsibilities. The board believes that its structure enables
it to effectively oversee risk management.
The board has standing audit and compensation committees, but
does not have a standing nominating committee. Further
information regarding these committees and the director
nomination process is provided below.
The Audit Committee, which met seven times in 2009,
monitors our financial reporting standards and practices and our
internal financial controls to ensure compliance with the
policies and objectives established by the board of directors.
The committee directly retains and recommends for stockholder
approval an independent accounting firm to conduct the annual
audit, and discusses with our independent accountants the scope
of their examinations, with particular attention to areas where
either the committee or the independent accountants believe
special emphasis should be directed. The committee reviews the
quarterly and annual financial statements and the annual
independent accountants report, invites the
accountants recommendations on internal controls and on
other matters, and reviews the evaluation given and corrective
action taken by management. It reviews the independence of the
accountants and pre-approves audit and permissible non-audit
services. It also reviews our internal accounting controls and
the scope and results of our internal auditing activities.
Members of the audit committee are Lawrence S. Burstein, Jerome
Baron, Evan Jones and Kenneth Weisshaar. Mr. Weisshaar
joined the Audit Committee upon his appointment to the board in
April 2010. Each member of the committee is independent as
defined in
Rule 10A-3
of the Securities and Exchange Commission and the listing
standards of the Nasdaq Stock Market. The board of directors has
determined that each of Lawrence S. Burstein, Jerome Baron, Evan
Jones and Kenneth Weisshaar qualifies as an audit
committee financial expert as that term is defined in
Regulation S-K
of the Securities and Exchange Commission.
The Compensation Committee, which met twice in 2009,
oversees our executive and director compensation programs,
including establishing our executive and director compensation
policies and annually reviewing all components of compensation
to ensure that our objectives are
8
appropriately achieved. These functions are not delegated to our
officers or to third-party professionals, although the committee
may from time to time retain third-party consultants to provide
advice regarding compensation issues. No such consultants were
retained during 2009. The committee also considers input from
our executive officers although final decisions regarding
executive compensation are made by the committee. The committee
is also responsible for certain administrative aspects of our
compensation plans and stock plans, and approves or recommends
changes in these plans. It also approves performance targets and
grants under our incentive plans and our stock plan for our
executive officers. The committee also reviews officers
potential for growth, and, with the chief executive officer,
will be responsible for succession planning and ensuring
management continuity. The members are Lawrence S. Burstein,
Jerome Baron and Evan Jones.
Each committee is governed by a written charter. Copies of each
committee charter are available on our website at www.casmed.com.
Director
Compensation
Director Fees. We pay our non-employee
directors an annual retainer. The Chairman of the Board receives
$25,000 and each other director receives $20,000. We also pay an
annual retainer of $4,000 to the Audit Committee chairman and
$2,000 to the Compensation Committee chairman and pay an annual
retainer of $2,000 to each other Audit Committee member and
$1,000 to each other Compensation Committee member. During 2009,
we paid total annual fees of $78,750 to the non-employee
directors and a total of $12,000 in fees to the non-employee
directors for their participation as committee members.
Our non-employee directors are eligible to receive options,
restricted stock and other equity-linked grants under our 2003
Equity Incentive Plan. On June 10, 2009, we granted
5,882 shares of restricted common stock under the 2003
Equity Incentive Plan to each of Messrs. Baron, Burstein,
Jones and Scheps. The grants were intended to approximate
$10,000 in cash value based upon the market value of the common
stock at the date of grant. These restricted stock grants vest
in equal quarterly installments during the twelve months from
date of grant.
In 2010, the board intends to grant to each non-employee
director, on the date of the annual meeting of stockholders, a
number of restricted shares equal to $10,000 divided by the
closing price of the common stock on such date. The
aforementioned grant would vest quarterly from the date of grant
over a
one-year
period.
Director Compensation Table. The following
table shows all compensation paid or granted, during or with
respect to the 2009 fiscal year to each of the non-employee
directors for services rendered to CASMED during 2009.
2009
DIRECTOR COMPENSATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fees Earned or
|
|
Stock
|
|
All Other
|
|
|
Name (a)
|
|
Paid in Cash ($)
|
|
Awards ($)(b)
|
|
Compensation ($)
|
|
Total ($)
|
|
Jerome Baron
|
|
$
|
25,000
|
|
|
$
|
10,000
|
|
|
$
|
0
|
|
|
$
|
35,000
|
|
Lawrence S. Burstein
|
|
$
|
23,000
|
|
|
$
|
10,000
|
|
|
$
|
0
|
|
|
$
|
23,000
|
|
Evan Jones
|
|
$
|
24,000
|
|
|
$
|
10,000
|
|
|
$
|
0
|
|
|
$
|
34,000
|
|
Louis P. Scheps (c)
|
|
$
|
18,750
|
|
|
$
|
10,000
|
|
|
$
|
26,923
|
|
|
$
|
55,673
|
|
Kenneth R. Weisshaar (d)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(a) |
|
As of December 31, 2009, Mr. Baron held an option to
purchase 7,500 shares of our common stock,
Mr. Burstein held options and warrants to purchase an
aggregate of 115,000 shares of our common stock,
Mr. Jones held an option to purchase an aggregate of
20,000 shares of our common stock and Mr. Scheps held
warrants to purchase 714,401 shares of our common stock. As
of December 31, 2009, Messrs. Baron, Burstein, Jones
and Scheps each held 2,941 shares of restricted stock. |
9
|
|
|
(b) |
|
Dollar amounts represent the fair market value of
5,882 shares of restricted stock granted to each outside
director on June 10, 2009. The fair market value of the
grants was $1.70 per share representing the closing market price
on the date of grant. The shares vest quarterly over a one year
period from grant date. |
|
(c) |
|
Mr. Scheps served as a part-time employee in a senior
executive role through March 31, 2009 at an annualized
salary of $100,000. This payment is reflected in the column
entitled All Other Compensation. |
|
(d) |
|
Mr. Weisshaar was not a member of the Board of Directors
during 2009. |
Communications
with Directors
In order to provide our security holders and other interested
parties with a direct and open line of communication to the
board of directors, the board of directors has adopted the
following procedures. CASMED security holders and other
interested persons may communicate with the chairmen of our
Compensation Committee or Audit Committee or with the
non-management directors as a group by sending written
correspondence to our Secretary. The correspondence should
specify which of the foregoing is the intended recipient.
Communications should be sent by mail addressed in care of the
corporate Secretary, CAS Medical Systems, Inc., 44 East
Industrial Road, Branford, Connecticut 06405.
All communications received in accordance with these procedures
will be reviewed initially by our corporate Secretary. The
Secretary will relay all such communications to the appropriate
director or directors unless the Secretary determines that the
communication:
|
|
|
|
|
does not relate to the business or affairs of CASMED or the
functioning or constitution of the board of directors or any of
its committees;
|
|
|
|
relates to routine or insignificant matters that do not warrant
the attention of the board of directors;
|
|
|
|
is an advertisement or other commercial solicitation or
communication;
|
|
|
|
is frivolous or offensive; or
|
|
|
|
is otherwise not appropriate for delivery to directors.
|
The director or directors who receive any such communication
will have discretion to determine whether the subject matter of
the communication should be brought to the attention of the full
board of directors or one or more of its committees and whether
any response to the person sending the communication is
appropriate. Any response will be made only in accordance with
applicable law and regulations relating to the disclosure of
information.
Our Secretary will retain copies of all communications received
pursuant to these procedures for a period of at least one year.
The board of directors will review the effectiveness of these
procedures from time to time and, if appropriate, recommend
changes.
We have not established a formal policy regarding director
attendance at our annual meetings of stockholders, but our
directors generally do attend the annual meeting. The chairman
of the board presides at the annual meeting of stockholders, and
the board of directors generally holds one of its regular
meetings in conjunction with the annual meeting of stockholders.
Accordingly, unless one or more members of the board are unable
to attend, all members of the board are present for the annual
meeting. Each of the five members of the board at the time of
our 2009 annual meeting of stockholders attended that meeting.
Nomination
of Directors
Due to the small size of our board of directors, the board of
directors determined that it is appropriate for the full board
to act with respect to director nomination matters. Four of the
six board members are independent as set forth in the rules of
the Nasdaq Stock Market. The full board has adopted
specifications applicable to members of the board of directors,
and nominees for the board of directors recommended by the board
of directors must meet these specifications.
10
The specifications provide that a candidate for director should:
|
|
|
|
|
Have a reputation for industry, integrity, honesty, candor,
fairness and discretion;
|
|
|
|
Be knowledgeable in his or her chosen field of endeavor, which
field should have such relevance to our businesses as would
contribute to the companys success;
|
|
|
|
Be knowledgeable, or willing and able to become so quickly, in
the critical aspects of our businesses and operations; and
|
|
|
|
Be experienced and skillful in serving as a competent overseer
of, and trusted advisor to, senior management of a publicly held
corporation.
|
In addition, nominees for the board of directors should
contribute to the mix of skills, core competencies and
qualifications of the board through expertise in one or more of
the following areas: accounting and finance, the healthcare
industry, international business, mergers and acquisitions,
leadership, business and management, strategic planning,
government relations, investor relations, executive leadership
development, and executive compensation.
Mr. Weisshaar, who joined the board in 2010, was
recommended to the Board by one of our current non-employee
directors, Mr. Jones. We did not employ a third party to
undertake a search for this position.
The board of directors also seeks nominees who will contribute
to the boards diversity. While the board of directors does
not maintain a formulaic policy or approach with respect to
diversity, it continually seeks a wide range of perspectives and
experiences among its members.
The board will consider nominees recommended by stockholders for
election at the 2011 annual meeting of stockholders that are
submitted prior to the end of 2010 to our Secretary at CAS
Medical Systems, Inc., 44 East Industrial Road, Branford,
Connecticut 06405. Any recommendation must be in writing and
must include a detailed description of the business experience
and other qualifications of the recommended nominee as well as
the signed consent of the nominee to serve if nominated and
elected, so that the candidate may be properly considered. All
stockholder recommendations will be reviewed in the same manner
as other potential candidates for board membership.
The board has not received any nominees for election to the
board at the 2010 annual meeting from any stockholder or group
that has held more than 5% of our common stock for a period of
one year.
Code of
Ethics
Our board of directors has approved a Code of Ethics in
accordance with the rules of the Securities and Exchange
Commission and The Nasdaq Stock Market that governs the conduct
of each of our directors and senior executive officers,
including our principal executive officer, principal financial
officer, principal accounting officer and controller. Our Code
of Ethics is maintained on our website at www.casmed.com. Any
amendments to or waivers of the Code of Ethics that apply to our
principal executive officer, principal financial officer or
principal accounting officer and that relates to any element of
the definition of the term code of ethics, as the
term is defined by the Securities and Exchange Commission, will
be posted on our website at www.casmed.com. There are currently
no such amendments or waivers.
We recognize the importance of preventing both actual conflicts
of interest and the appearance of such conflicts in dealings
between CASMED and related persons (CASMED
directors, director nominees, executive officers, stockholders
owning five percent or greater of our common stock or the
immediate family members of any of the foregoing). In accordance
with its charter, the Audit Committee regularly reviews our
corporate policies with respect to conflicts of interest
including related party transactions and investigates instances
of such conflicts.
Executive
Officer Compensation
Executive
Contracts and Severance and Change of Control
Arrangements
Andrew E. Kersey. On August 10, 2009, we
entered into an employment agreement with Andrew E. Kersey, our
President and Chief Executive Officer. This agreement supersedes
11
Mr. Kerseys previous agreement dated March 16,
2007 as amended December 29, 2008. Under the terms of the
employment agreement, Mr. Kersey is employed on an at
will basis, will receive an annual base salary of two
hundred fifty thousand dollars ($250,000) and will be eligible
for an annual bonus in the form of cash or CASMED common stock
as determined at the sole discretion of the Compensation
Committee of the board. Mr. Kersey will also be entitled to
participate in all of our employee benefit programs as such
programs may be in effect from time to time.
If we terminate Mr. Kerseys employment without
Serious Cause (as defined in the Employment Agreement) or
Mr. Kersey terminates his employment for Good Reason (as
defined in the Employment Agreement), we will continue to pay
Mr. Kersey his then- current base salary for a period of
six (6) months from the date of such termination and he
will be entitled to participate in our health benefit plans
(with standard employee payment not to exceed the payment level
prior to termination) for the six (6) month period. This
would represent a payment of approximately $127,600 based upon
his current salary and benefits level. In addition, if
Mr. Kersey terminates his employment for Good Reason or if
we terminate Mr. Kerseys employment without Serious
Cause, all of Mr. Kerseys equity-linked grants (such
as stock options and restricted stock) shall immediately
accelerate and vest in full. If we (or a successor company)
terminate Mr. Kerseys employment without Serious
Cause or Mr. Kersey terminates his employment for Good
Reason, within the period commencing on the date that a Change
of Control (as defined in the Employment Agreement) is formally
proposed to our board of directors and ending on the second
anniversary of the date on which such Change of Control occurs,
then Mr. Kersey will be entitled to receive his
then-current base salary for a period of one (1) year from
the date of such termination and in addition will be entitled to
participate in our health benefit plans (with standard employee
payment not to exceed the payment level prior to the change in
control) for the period of one (1) year. This would
represent a payment of approximately $255,200 based upon his
current salary and benefits level.
Jeffery A. Baird. On August 10, 2009, we
entered into an employment agreement with Jeffery A. Baird
pursuant to which Mr. Baird is serving as our Chief
Financial Officer. Under the terms of the employment agreement,
Mr. Baird is employed on an at will basis, will
receive an annual base salary of two hundred thousand dollars
($200,000) and will be eligible for an annual bonus in the form
of cash or CASMED common stock as determined at the sole
discretion of the Compensation Committee of the board.
Mr. Baird will also be entitled to participate in all of
our employee benefit programs as such programs may be in effect
from time to time.
If we terminate Mr. Bairds employment without Serious
Cause (as defined in the Employment Agreement) or Mr. Baird
terminates his employment for Good Reason (as defined in the
Employment Agreement), we will continue to pay Mr. Baird
his then-current base salary for a period of six (6) months
from the date of such termination and he will be entitled to
participate in our health benefit plans (with standard employee
payment not to exceed the payment level prior to termination)
for the six (6) month period. This would represent a
payment of approximately $97,800 based upon his current salary
and benefits level. In addition, if Mr. Baird terminates
his employment for Good Reason or if we terminate
Mr. Bairds employment without Serious Cause, all of
Mr. Bairds equity-linked grants (such as stock
options and restricted stock) shall immediately accelerate and
vest in full. If we (or a successor company) terminate
Mr. Bairds employment without Serious Cause or
Mr. Baird terminates his employment for Good Reason, within
the period commencing on the date that a Change of Control (as
defined in the Employment Agreement) is formally proposed to our
board of directors and ending on the second anniversary of the
date on which such Change of Control occurs, then Mr. Baird
will be entitled to receive his then-current base salary for a
period of one (1) year from the date of such termination
and in addition will be entitled to participate in our health
benefit plans (with standard employee payment not to exceed the
payment level prior to the change in control) for the period of
one (1) year. This would represent a payment of
approximately $195,600 based upon his current salary and
benefits level.
12
Compensation
Discussion and Analysis
Our Compensation Committee, which is comprised of three
independent non-employee directors, has formulated a
compensation philosophy that is designed to enable us to
attract, retain and reward capable employees who can contribute
to the success of CASMED, principally through a combination of
(1) base salaries, (2) annual incentive opportunities
and (3) longer term incentive opportunities for senior
management. We believe that implementation of a system of
compensation that emphasizes performance-based compensation
provides a strong alignment to stockholders interests.
Five key principles serve as the guiding framework for
compensation decisions for all executive officers of CASMED:
|
|
|
|
|
To attract and retain the most highly qualified management and
employee team.
|
|
|
|
To pay competitively compared to similar companies in our
industry.
|
|
|
|
To encourage superior employee performance by aligning rewards
with stockholder interests.
|
|
|
|
To motivate senior executives to achieve CASMEDs annual
and long-term business goals by providing equity-based incentive
opportunities.
|
|
|
|
To strive for fairness in administration by emphasizing
performance related contributions as the basis for pay decisions.
|
To implement these policies, we have designed the framework for
a four-part executive compensation program consisting of base
salary, annual incentives, long-term incentive opportunities for
senior management, and other employment benefits.
Base Salary. We will seek to maintain levels
of compensation that are competitive with similar companies in
our industry. Base salary represents the fixed component of the
executive compensation program. CASMEDs philosophy
regarding base salaries is to maintain salaries for the
aggregate officer group at the competitive industry average.
Periodic increases in base salary will relate to individual
contributions evaluated against established objectives, length
of service, and the industrys annual competitive pay
practice movement. We believe that base salary for 2009 for our
chief executive officer and for the other executive officers was
generally at the competitive industry average.
Annual Incentive Program. Each year the
Compensation Committee assesses whether to pay bonuses to our
employees including senior executives either in cash or stock
based upon performance. Payment of the performance bonuses is at
the sole discretion of the Compensation Committee and is not
based on specific metrics, although the Compensation Committee
bases its decisions on numerous factors, including overall
corporate and personal performance. No cash bonus payments were
made to the named executive officers for 2009.
Long-Term Incentives. We believe that
long-term incentives should provide senior executives with an
opportunity to increase their ownership and potentially gain
financially from CASMED stock price increases. By this approach,
the best interests of stockholders and senior executives will be
closely aligned. Therefore, senior executives are eligible to
receive restricted stock and are also eligible to receive stock
options, giving them the right to purchase shares of common
stock at a specified price in the future. These grants will vest
based upon the passage of time, the achievement of performance
metrics, or both. We believe that the use of restricted stock
and stock options as the basis for long-term incentive
compensation meets our defined compensation strategy and
business needs by achieving increased value for stockholders and
retaining key employees.
Other Benefits. Our philosophy is to provide
competitive health and welfare-oriented benefits to executives
and employees, but to maintain a conservative posture relative
to executive benefits. We do provide life insurance and
supplemental disability insurance to our senior executive
officers.
Compliance with Section 162(m) of the Internal Revenue
Code. Section 162(m) of the Internal Revenue
Code generally disallows a tax deduction to a public corporation
for compensation over $1 million paid to a
corporations chief executive officer and four other most
highly compensated executive officers. Qualifying
performance-based compensation will not be subject to the cap if
certain requirements are met. The salaries for our
13
highest paid executives will be set, in part based on
independent studies, at the competitive industry average but are
not expected to reach $1 million in the near future. We
intend to structure the overall compensation of our executive
officers in a manner that should ensure that CASMED does not
lose any tax deductions because of the $1 million
compensation limit in the foreseeable future.
Our 2003 Equity Incentive Plan incorporates maximum limitations
on individual annual stock option and restricted stock grants so
as to meet the requirements of Section 162(m). The 2003
Equity Incentive Plan also identifies performance measures to be
used if we decide to use performance-based vesting restricted
stock in the future to meet the requirements of
Section 162(m).
Compensation
Disclosure Tables
Summary Compensation Table. The following
table (Table I) shows all compensation paid or granted,
during or with respect to the 2008 and 2009 fiscal years to
(i) our chief executive officer and (ii) the other
most highly compensated executive officer, other than the CEO,
whose total compensation during 2009 exceeded $100,000 and who
was serving as an executive officer as of December 31, 2009
and (iii) one former executive officer whose total
compensation exceeded $100,000 during 2009. (Persons in this
group are referred to individually as a named executive
officer and collectively as the named executive
officers, and, unless otherwise noted, the titles listed
are the titles held as of the end of the 2009 fiscal year.)
TABLE
I
2008-2009
SUMMARY COMPENSATION TABLE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
All
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
Option
|
|
Plan
|
|
Other
|
|
|
|
|
|
|
Salary
|
|
Bonus
|
|
Awards
|
|
Awards
|
|
Compensation
|
|
Compensation
|
|
Total
|
Name and Principal Position
|
|
Year
|
|
($)
|
|
($)
|
|
($) (a)
|
|
($) (a)
|
|
($)
|
|
($) (b)
|
|
($)
|
|
Andrew E. Kersey
|
|
|
2009
|
|
|
$
|
242,055
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
2,622
|
|
|
$
|
244,677
|
|
President and Chief Executive Officer
|
|
|
2008
|
|
|
$
|
245,192
|
|
|
$
|
0
|
|
|
$
|
87,000
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
2,535
|
|
|
$
|
334,727
|
|
Jeffery A. Baird
|
|
|
2009
|
|
|
$
|
193,614
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
3,544
|
|
|
$
|
197,158
|
|
Chief Financial Officer
|
|
|
2008
|
|
|
$
|
196,154
|
|
|
$
|
0
|
|
|
$
|
65,250
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
3,457
|
|
|
$
|
264,861
|
|
Nathan B. Harris
|
|
|
2009
|
|
|
$
|
139,457
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
139,457
|
|
Former Vice President Sales and Marketing (c)
|
|
|
2008
|
|
|
$
|
63,500
|
|
|
$
|
0
|
|
|
$
|
79,000
|
|
|
$
|
165,200
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
307,700
|
|
|
|
|
(a) |
|
Dollar amounts set forth with regard to restricted stock and
stock options grants are computed in accordance with FASB ASC
Topic 718. Share value utilized for purposes of this
determination is the applicable fair market value on the date of
grant. Fair market value utilized for restricted stock grants
represents the closing market price on the date of grant. Fair
market value utilized for stock option grants are based upon on
a Black-Scholes calculation assuming a 3.6% risk free interest
rate, volatility of 63%, a term of seven years and an annual
dividend rate of zero. For a further discussion of the
assumptions underlying these amounts, reference is made to the
footnotes to CASMEDs financial statements set forth in
Form 10-K
for the fiscal year ended December 31, 2009. |
|
|
|
(b) |
|
Amounts shown consist of the cost of term life and disability
insurance for Messrs. Kersey and Baird. |
|
(c) |
|
Mr. Harris joined the Company on September 15, 2008
and resigned August 15, 2009. |
14
Grants of Plan-Based Awards Table. There were
no equity or non-equity grants made by CASMED during the 2009
fiscal year to the named executive officers.
Outstanding Equity Awards at Fiscal Year-End
Table. Shown in Table II below is
information with respect to outstanding equity-based awards
(consisting of unexercised options to purchase CASMED common
stock and unvested restricted CASMED common stock) held by the
named executive officers at December 31, 2009.
TABLE
II
OUTSTANDING
EQUITY AWARDS AT 2009 FISCAL YEAR END
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
|
|
|
|
|
|
Number of
|
|
Number of
|
|
|
|
|
|
Stock Awards
|
|
|
Securities
|
|
Securities
|
|
|
|
|
|
Number of
|
|
Market Value
|
|
|
Underlying
|
|
Underlying
|
|
|
|
|
|
Shares or Units
|
|
of Shares or
|
|
|
Unexercised
|
|
Unexercised
|
|
Option
|
|
Option
|
|
of Stock That
|
|
Units of Stock
|
|
|
Options (#)
|
|
Options (#)
|
|
Exercise
|
|
Expiration
|
|
Have Not
|
|
That Have Not
|
Name
|
|
Exercisable
|
|
Unexercisable
|
|
Price ($)
|
|
Date
|
|
Vested (#)
|
|
Vested ($) (a)
|
|
Andrew E. Kersey
|
|
|
50,000
|
|
|
|
0
|
|
|
$
|
0.57
|
|
|
|
10/11/2011
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
0
|
|
|
$
|
0.70
|
|
|
|
7/17/2013
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
0
|
|
|
$
|
1.50
|
|
|
|
6/2/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
0
|
|
|
$
|
2.30
|
|
|
|
2/17/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
0
|
|
|
$
|
3.10
|
|
|
|
6/15/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,001
|
|
|
$
|
31,802
|
|
Jeffery A. Baird
|
|
|
50,000
|
|
|
|
0
|
|
|
$
|
1.40
|
|
|
|
1/6/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
0
|
|
|
$
|
2.30
|
|
|
|
2/17/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
0
|
|
|
$
|
3.10
|
|
|
|
6/15/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,500
|
|
|
$
|
24,380
|
|
Nathan B. Harris
|
|
|
0
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
0
|
|
|
|
|
(a) |
|
These values are based on $2.12 per share, the market price of a
share of CASMED common stock as of December 31, 2009 (the
final trading day of 2009). |
Option Exercises and Stock Vested Table. The
following table (Table III) shows information with respect
to all stock options or warrants exercised by the named
executive officers during 2009 and information regarding
restricted stock held by those persons that vested during 2009.
TABLE
III
OPTION
EXERCISES AND STOCK VESTED TABLE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
Stock Awards
|
|
|
|
|
|
|
Number of
|
|
|
|
|
Number of
|
|
|
|
Shares
|
|
Value
|
|
|
Shares Acquired
|
|
Value Realized
|
|
Acquired on
|
|
Realized on
|
|
|
on Exercise
|
|
on Exercise
|
|
Vesting
|
|
Vesting
|
Name
|
|
(#)
|
|
($)
|
|
(#)
|
|
$
|
|
Andrew E. Kersey
|
|
|
|
|
|
|
|
|
|
|
8,333
|
|
|
$
|
13,133
|
|
Jeffery A. Baird
|
|
|
|
|
|
|
|
|
|
|
6,500
|
|
|
$
|
10,320
|
|
Nathan B. Harris
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
0
|
|
15
Equity Compensation Plan Table. The following
table (Table IV) sets forth general information concerning
our equity compensation plans as of December 31, 2009.
TABLE
IV
EQUITY
COMPENSATION PLAN INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of securities
|
|
|
|
|
|
|
|
|
|
remaining available for
|
|
|
|
Number of securities
|
|
|
Weighted-average
|
|
|
issuance under equity
|
|
|
|
to be issued upon
|
|
|
exercise price of
|
|
|
compensation plans
|
|
|
|
exercise of outstanding
|
|
|
outstanding options,
|
|
|
(excluding securities
|
|
|
|
options, warrants and
|
|
|
warrants and rights
|
|
|
reflected in column (a))
|
|
Plan Category
|
|
rights (col. a)
|
|
|
($) (col. b)
|
|
|
(col. c)
|
|
|
Equity compensation plans approved by security holders: (a)
|
|
|
488,175
|
|
|
$
|
2.19
|
|
|
|
402,273
|
|
Equity compensation plans not approved by security
holders: (a)
|
|
|
964,401
|
|
|
$
|
0.50
|
|
|
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
1,452,576
|
|
|
$
|
1.03
|
|
|
|
402,273
|
|
|
|
|
(a) |
|
The equity compensation plans not approved by security holders
consist of warrants granted to the chairman of the board of
directors, a former director, and current outside directors of
the company as compensation for services rendered to the
company. These warrants generally have no specific expiration
date and have an exercise price range of $0.30 to $1.44. Equity
compensation plans approved by security holders consist of the
1994 Employees Incentive Stock Option Plan (referred to as
the 1994 Plan) and the 2003 Equity Incentive Plan. The 1994 Plan
expired on December 31, 2003 and, as such, there are no
further options available for issuance thereunder. |
16
Audit
Committee Report
The Audit Committee reviews CASMEDs financial reporting
function on behalf of the board of directors. Management has the
primary responsibility for preparing the financial statements in
accordance with accounting standards generally accepted in the
United States and the reporting process, including the system of
internal controls. CASMEDs independent accountants are
responsible for expressing an opinion on the annual financial
statements as to whether or not they are presented in conformity
in all material respects with accounting principles generally
accepted in the United States. The Audit Committee monitors
these processes through periodic meetings with management and
the independent registered public accounting firm.
In this context, the Audit Committee has reviewed and discussed
with management and the independent accountants the audited
financial statements for the year ended December 31, 2009,
including the audit scope, internal control matters, and audit
results. The Audit Committee also met with the independent
accountants without management present. The Audit Committee has
discussed with the independent accountants the matters required
to be discussed by auditing standards. In addition, the Audit
Committee has received from the independent accountants the
written disclosures and letter required by the applicable
requirements of the Public Company Accounting Oversight Board
regarding the independent accountants communications with
the Audit Committee concerning independence, and discussed with
them their independence from CASMED and its management. The
Audit Committee has also considered whether all non-audit
services rendered by the independent accountants to CASMED are
compatible with the accountants independence.
In reliance on the reviews and discussions referred to above,
the Audit Committee recommended to the board of directors, and
the board has approved, that the financial statements for the
year ended December 31, 2009 be included for filing in
CASMEDs annual report on
Form 10-K
for the year ended December 31, 2009.
Audit
Committee of the Board of Directors
Jerome Baron
Lawrence S. Burstein
Evan Jones
Kenneth R. Weisshaar
Audit
Committee Pre-Approval Policy
The Audit Committee operates under a written charter. Under this
charter, the Audit Committee is responsible for selecting,
approving, compensating and overseeing the independence,
qualifications and performance of the independent accountants.
Further, the Audit Committee has adopted a pre-approval policy
pursuant to which certain permissible non-audit services may be
provided by the independent accountants. Pre-approval is
generally provided for up to one year and may be detailed as to
the particular service or category of services and may be
subject to a specific budget. The Audit Committee may also
pre-approve particular services on a
case-by-case
basis. In assessing requests for services from the independent
accountants by management, the Audit Committee considers whether
such services are consistent with the auditors
independence; whether the independent accountants are likely to
provide the most effective and efficient service based upon
their familiarity with the company; and whether the service
could enhance our ability to manage or control risk or improve
audit quality.
Notwithstanding the pre-approval policy, all of the
audit-related, tax and other services provided by UHY LLP in
fiscal year 2009 were approved in advance by the Audit Committee.
17
Proposal 2:
Approval
of Appointment of CASMEDs Independent
Accountants
The Audit Committee of our board of directors has selected J.H.
Cohn LLP as our independent registered public accounting firm
for the year ending December 31, 2010, and has directed
that the selection of independent accountants be submitted for
ratification by stockholders at the annual meeting. A
representative of J.H. Cohn LLP is expected to be present at the
annual meeting and will have an opportunity to make a statement
if he or she desires and will be available to respond to
appropriate questions.
Stockholder ratification of the selection of J.H. Cohn LLP as
our independent accountants is not required by our Bylaws or
otherwise. However, the Audit Committee is submitting the
selection of J.H. Cohn LLP to the stockholders for ratification
as a matter of good corporate practice. If the stockholders fail
to ratify the selection, the Audit Committee will reconsider
whether or not to retain that firm. Even if the selection were
ratified, the Audit Committee in its discretion may direct the
appointment of a different independent accounting firm at any
time during the year if the Audit Committee determines that such
a change would be in the best interests of CASMED and its
stockholders.
Change of
Independent Accountants
On April 19, 2010 UHY LLP (UHY), our prior
independent registered public accounting firm, informed us that
effective April 16, 2010, its New England practice was
acquired by Marcum LLP. UHY also informed us that, as a result
of this transaction, it declined reappointment as our
independent registered public accounting firm for the fiscal
year ending December 31, 2010.
UHY audited our financial statements for the fiscal years ended
December 31, 2009 and 2008. The audit reports of UHY on our
financial statements for those years did not contain an adverse
opinion, or a disclaimer of opinion, or qualification or
modification as to any uncertainty, audit scope, or accounting
principles.
During the fiscal years ended December 31, 2009 and 2008
and subsequently to April 19, 2010, there were no
disagreements with UHY on any matter of accounting principles or
practices, financial statement disclosure, or auditing scope or
procedure that, if not resolved to UHYs satisfaction,
would have caused UHY to make reference to the subject matter of
the disagreement in connection with its audit reports nor were
there any reportable events (as that term is
described in Item 304(a)(1)(v) of
Regulation S-K).
UHY issued a letter dated April 21, 2010 addressed to the
Securities and Exchange Commission stating that UHY agreed with
the above statements.
Through March 2010, UHY had a continuing relationship with UHY
Advisors, Inc. (Advisors). Under this relationship
UHY leased auditing staff who were full time, permanent
employees of Advisors. UHY partners provide non-audit services
through Advisors. UHY has only a few full time employees.
Therefore, few, if any, audit services performed were provided
by permanent full-time employees of UHY. UHY manages and
supervises the audit services and audit staff, and is
exclusively responsible for the opinion rendered in connection
with its audit.
Our audit committee appointed J.H. Cohn LLP as the successor
independent registered public accounting firm on April 21,
2010. Prior to such appointment, we had not consulted with J.H.
Cohn LLP with respect to: 1) the application of accounting
principles to a specified transaction, either completed or
proposed; 2) the type of audit opinion that might be
rendered on our financial statements; or 3) any matter that
was either the subject of a disagreement (as defined in
Item 304(a)(1)(iv) of
Regulation S-K)
or a reportable event (as described in Item 304(a)(1)(v) of
Regulation S-K).
The audit committee made its determination based in part on
maintaining continuity of service due to the current UHY lead
account partner joining J.H. Cohn LLP.
Audit
Fees
J.H. Cohn LLP has not performed any services to CASMED for the
years ended 2009 or prior.
18
UHY LLP performed the audit of our annual consolidated financial
statements included in the annual report on
Form 10-K
and the review of interim consolidated financial statements
included in quarterly reports on
Form 10-Q
and the review and audit of the application of new accounting
pronouncements and SEC releases. Aggregate fees billed by UHY
LLP were $147,386 and $154,820 for the years ended
December 31, 2009 and 2008, respectively.
Audit-Related
Fees
UHY LLP also provided 401(K) Plan audit services to the Company
during 2009 and 2008 for the plan years ended December 31,
2008 and 2007. Fees billed by UHY LLP for those services were
$12,666 and $12,647, respectively.
Tax
Fees
UHY LLP did not provide tax services to CASMED during the years
ended December 31, 2009 and 2008.
All Other
Fees
UHY LLP did not provide any services in addition to those
described above during the years ended December 31, 2009
and 2008.
The board of directors recommends that stockholders vote FOR
the appointment of J.H. Cohn LLP as the companys
independent accountants for 2010.
Additional
Information
Solicitation
of Proxies
In addition to the use of the mails, proxies may be solicited by
the directors, officers, and employees of the company without
additional compensation in person, or by telephone, facsimile,
email or otherwise. Arrangements may also be made with brokerage
firms and other custodians, nominees, and fiduciaries for the
forwarding of solicitation material to the beneficial owners of
CASMED common stock, and we will reimburse these brokers,
custodians, nominees, and fiduciaries for reasonable
out-of-pocket
expenses incurred. The cost of solicitation will be borne
entirely by CASMED.
Other
Matters
Directions to the annual meeting can be obtained by making a
written or oral request to our Secretary,
c/o CAS
Medical Systems, Inc., 44 East Industrial Road, Branford,
Connecticut 06405 or by telephone
(203-488-6056).
Management knows of no other matters which may be presented for
consideration at the meeting. However, if any other matters
properly come before the meeting, it is the intention of the
individuals named in the enclosed proxy to vote in accordance
with their judgment.
By order of the board of directors.
Jeffery A. Baird
Secretary
19
ANNUAL MEETING OF STOCKHOLDERS OF
CAS MEDICAL SYSTEMS, INC.
June 9, 2010
NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIAL:
The Notice of Meeting, proxy statement and proxy card
are available at www.casmed.com
Please sign, date and mail
your proxy card in the
envelope provided as soon
as possible.
¯
Please detach along perforated line and mail in the envelope provided. ¯
|
|
|
|
|
|
|
▀
|
|
|
20630000000000000000 6 |
|
|
060910 |
|
|
|
|
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE
ELECTION OF DIRECTORS AND FOR PROPOSAL 2.
|
x |
|
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN
HERE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FOR
|
|
AGAINST
|
|
ABSTAIN |
1. |
Election of Directors.
|
|
|
2. |
|
To ratify the selection of J. H. Cohn LLP as
independent auditors for the Companys fiscal year ending December 31, 2010.
|
|
o |
|
o |
|
o |
|
|
|
NOMINEES: |
|
|
|
|
|
|
|
|
o
|
|
FOR ALL NOMINEES |
¡ ¡ |
Jerome Baron Lawrence S. Burstein |
|
|
|
|
|
|
|
o
|
|
WITHHOLD
AUTHORITY FOR ALL NOMINEES |
¡ ¡ ¡ |
Evan Jones Andrew E. Kersey Louis P. Scheps |
|
|
|
|
|
|
To transact such other business as may properly come before the annual meeting.
|
o |
|
FOR ALL EXCEPT (See Instructions below) |
¡ |
Kenneth R. Weisshaar |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
This proxy, when properly executed, will be voted in the manner
directed by the undersigned stockholder. If no direction is made, this proxy
will be voted FOR proposals 1 and 2. Please sign exactly as name appears on the left.
|
INSTRUCTION: To withhold
authority to vote for any individual nominee(s), mark FOR ALL EXCEPT and fill in the circle next to each nominee you wish
to withhold, as shown here:
=
|
|
|
PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY USING THE ENCLOSED ENVELOPE. |
|
|
|
To change the address on your account, please check the box at right and indicate your new address in the address space above. Please note
that changes to the registered name(s) on the account may not be submitted via this method.
|
o |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature
of Stockholder
|
|
Date:
|
|
Signature
of Stockholder
|
|
Date:
|
|
|
|
|
|
|
|
|
▀ |
|
Note:
|
|
Please sign exactly as your name or names appear on this Proxy.
When shares are held jointly, each holder should sign. When signing as executor,
administrator, attorney, trustee or guardian, please give full title as such. If the signer
is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a
partnership, please sign in partnership name by authorized person.
|
▀ |
|
|
|
|
|
CAS MEDICAL SYSTEMS, INC.
44 East Industrial Road, Branford, Connecticut 06405
This Proxy is Solicited on Behalf of the Board of Directors
The undersigned hereby appoints Louis P. Scheps and Andrew E. Kersey, and each of them, as the true
and lawful attorneys, agents and proxies of the undersigned, each with full power of substitution, to represent and vote all shares of common stock of CAS Medical Systems, Inc. held of record by the undersigned on April 21, 2010 at the Annual Meeting of Stockholders to be held on June 9, 2010 and at any adjournment thereof, as specified on the reverse side of this proxy card and in their discretion upon such other matters as may properly come
before such Annual Meeting and at any adjournment thereof. Any and all proxies heretofore given are hereby revoked.
(Continued and to be signed on the reverse side)